Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes: A meta-analysis of placebo-controlled clinical trials

American Journal of Hypertension

Volumn 24, Issue 5, 2011, Pages 582-590

  Tocci, Giuliano ^a   Paneni, Francesco ^a   Palano, Francesca ^a   Sciarretta, Sebastiano ^a   Ferrucci, Andrea ^a   Kurtz, Theodore ^b   Mancia, Giuseppe ^c   Volpe, Massimo ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN GERARDO HOSPITAL   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

angiotensin II receptor blockers; angiotensin converting enzyme inhibitors; blood pressure; cardiovascular mortality; hypertension; meta analysis; new onset diabetes mellitus; non cardiovascular mortality; randomized clinical trials

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; DIABETES MELLITUS; DRUG EFFECT; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; INCIDENCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79954933210     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2011.8     Document Type: Article

References (42)

1. Kannel WB, McGee DL Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2:120-126. (Pubitemid 9238733)
2. Gandjour A, Kleinschmit F, Lauterbach KW; INTERCARE International Investigators. European comparison of costs and quality in the prevention of secondary complications in Type 2 diabetes mellitus (2000-2001). Diabet Med 2002; 19 594-601. (Pubitemid 35300682)
3. Haffner SM, Ruilope L, Dahlöf B, Abadie E, Kupfer S, Zannad F. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol 2006; 47:469-475. (Pubitemid 44309703)
4. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3-10. (Pubitemid 41819128)
5. Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension 2007; 50:459-460. (Pubitemid 47312227)
6. Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P, Sowers JR. Reversa of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study J Cardiometab Syndr 2008; 3:18-25.
7. Mozaffarian D, Marfisi R, Levantesi G, Silletta MG, Tavazzi L, Tognoni G, Valagussa F, Marchioli R. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle isk factors. Lancet 2007; 370:667-675. (Pubitemid 47285317)
8. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with β blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100:1254-1262. (Pubitemid 47498283)
9. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207. (Pubitemid 46111014)
10. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99:1006-1012. (Pubitemid 46483294)
11. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme nhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-an lyized clinica Coll Cardiol 2005; 46:821-826.
12. Muñoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats J Hypertens 2009; 27:2409-2420.
13. Aksnes TA, Seljeflot I, Torjesen PA, Höieggen A, Moan A, Kjeldsen SE. Improved nsulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007; 56:1470-1477. (Pubitemid 47562496)
14. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43:1003-1010. (Pubitemid 38579905)
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometric 1994; 50:1088-1101.
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
18. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC; Studies Of Left Ventricular Dysfunction. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107:1291-1296. (Pubitemid 36314413)
19. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR; DREAM Trial Investigators. Effect of amipril on the incidence of diabetes. N Engl J Med 2006; 355:1551-1562.
20. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre tria (the EUROPA study). Lancet 2003; 362:782-788. (Pubitemid 37093919)
21. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
22. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMOverall programme. Lancet 2003; 362:759-766. (Pubitemid 37093915)
23. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886. (Pubitemid 36677151)
24. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
25. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
26. Sawada T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30:2461-2469.
27. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM; NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
28. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588. (Pubitemid 44209181)
29. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B; HOPE Study Investigators. Ramipri and the development of diabetes. JAMA 2001; 286:1882-1885.
30. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P Anderson C; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
31. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009; 32:826-834.
32. Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P Klunge OH. Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 2009; 22:545-551.
33. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008; 21:493-499. (Pubitemid 351589673)
34. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes J Hypertens 2004; 22:1845-1847. (Pubitemid 39336662)
35. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K. Circulating angiotensin II is associated with body fat accumulation and nsulin resistance in obese subjects with type 2 diabetes mellitus. Metab Clin Exp 2009; 58:708-713.
36. Zhou MS, Schulman IH, Raij L Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol 2009; 296:H833-H839.
37. Grassi G, Seravalle G, Quarti-Trevano F, Mineo C, Lonati L, Facchetti R, Mancia G. Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea J Hypertens 2010; 28: 1313-1320.
38. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52:925-931.
39. Gustafsson T, Andersson P, Chen Y, Magnusson JO, Arnqvist HJ. Interaction of angiotensin II and the insulin-like growth factor system in vascular smooth muscle cells. Am J Physiol 1999; 277:H499-H507. (Pubitemid 29415962)
40. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE nhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002; 40:329-334. (Pubitemid 35006719)
41. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H. Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21:576-581. (Pubitemid 351589680)
42. Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P Lazzari P, Derosa G. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 2009; 41:893-898.